Seventh Circuit Sets 24 September Date for Lilly's Retatrutide Classification Appeal

What's New: A Hearing Date Is Finally on the Calendar

The US Court of Appeals for the Seventh Circuit has scheduled oral arguments for 24 September 2026 in Eli Lilly's appeal over how retatrutide should be legally classified — as a chemically synthesised drug reviewable under a New Drug Application (NDA), or as a biological product reviewable under a Biologics License Application (BLA). Trade and legal press have covered the fight as one that is “coming to a head” precisely because it is now running on a fixed court calendar rather than an open-ended timeline.[1]

We covered the full background of this dispute — the amino-acid counting argument at its centre, the September 2025 district court ruling, and Lilly's February 2026 notice of appeal — in our earlier report on the classification fight. This article focuses narrowly on what has changed since then: a confirmed hearing date, and why its timing against Lilly's own regulatory calendar matters.

Why Are Lilly and the FDA Still Arguing Over What Retatrutide Is?

In brief: Lilly sued the FDA in September 2024 after the agency decided retatrutide falls short of the regulatory definition of a “protein” — a >40-alpha-amino-acid polymer — because one non-amino-acid spacer in its structure, used to extend the molecule's half-life, doesn't count toward that threshold. Lilly argues the molecule is, at minimum, “analogous to a protein,” a category the same regulation separately recognises.[2]

A district court partially agreed in September 2025, vacating the FDA's reasoning as arbitrary and sending the question back to the agency — but stopping short of declaring retatrutide a biologic outright. Unsatisfied with a remand alone, Lilly appealed to the Seventh Circuit in February 2026, asking the appellate court to go further and order the reclassification directly.[2]

Why Does the Hearing's Timing Matter?

The September hearing lands roughly seven weeks after Eli Lilly's Q2 2026 earnings release on 5 August 2026, in which the company confirmed that retatrutide's clinical data package — spanning obesity, obstructive sleep apnea and knee osteoarthritis pain across the four core TRIUMPH trials plus the TRANSCEND-T2D-1 diabetes study — is now complete, and reaffirmed a Q1 2027 target to submit its US marketing application.[3] We covered that earnings confirmation in more detail in our Q2 2026 Phase 3 completion report.

That reaffirmed filing window is what turns a technical amino-acid-counting dispute into a live commercial question. Which application Lilly submits — BLA or NDA — determines the exclusivity period attached to the eventual approval: 12 years under the Biologics Price Competition and Innovation Act for a BLA, versus roughly five years of new-chemical-entity exclusivity for an NDA under the Hatch-Waxman framework, a gap financial press has estimated is worth billions of dollars over the product's commercial life. Our earlier guide covers this exclusivity math, along with the related Medicare drug-price-negotiation timing difference, in full.[1]

What Happens After the 24 September Hearing?

Federal appellate courts do not rule from the bench. After a three-judge panel hears oral arguments, it typically deliberates for weeks to several months before publishing a written opinion — and complex regulatory-classification questions like this one tend to sit toward the slower end of that range. That makes it plausible, though not certain, that a Seventh Circuit ruling could land close to, or even after, Lilly's own Q1 2027 filing target, rather than well ahead of it.

The two tracks are also not mutually exclusive. Separately from the appeal, the FDA itself remains under the district court's 2025 remand order to redo its classification analysis using a clearer standard; as of this writing, the agency has not issued a new determination. In principle, the FDA could rule on remand before the Seventh Circuit rules on the appeal, or the reverse — and whichever comes first could still be challenged further by the losing side. Lilly has stated it can proceed with a filing under either application type if the classification question remains unresolved at the time, meaning the litigation is not expected to delay the underlying regulatory submission itself.

Does This Affect UK Research-Reagent Supply?

No. This remains a US federal dispute over which American regulatory pathway a licensed pharmaceutical company must use to seek marketing approval for an investigational drug. It has no bearing on the UK regulatory position for research reagents, which sits under the Human Medicines Regulations 2012 and MHRA guidance — see our guide on whether research peptides are legal in the UK. Retatrutide remains unlicensed for human use everywhere, regardless of how the classification question or the September hearing resolve.

Retatrutide is supplied as a research reagent only. It is not a medicine and has not been evaluated by the MHRA or FDA. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.

Frequently Asked Questions